MTOR and B-cell chronic lymphocytic leukemia: Thus, with the coordinating results of our RPPA and inhibitor treatment comparisons in CLL patient samples, we demonstrate a rationale for considering mTOR-mediated mRNA translation as a therapeutic target in CLL.